{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115675","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.574106+00:00","generated_at":"2026-06-22T03:51:03.967161+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rhythm Q3 2022: IMCIVREE revenue $4.3M; net loss $40.9M; cash $347.8M","bullets":["Product revenue $4.3M vs $1.0M YoY; net loss $40.9M ($0.79/share) vs $35.1M ($0.70).","More than 120 IMCIVREE prescriptions written for BBS since FDA approval; 40+ approved for reimbursement.","FDA Breakthrough Therapy Designation for setmelanotide in hypothalamic obesity; Phase 3 trial to start early 2023.","Completed public offering netting $131.2M; extended cash runway into 2025.","Appointed Dana Washburn as SVP Clinical Development; EC expanded approval for IMCIVREE in BBS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115675","json":"https://secwatch.observer/filing/0001104659-22-115675.json","markdown":"https://secwatch.observer/filing/0001104659-22-115675.md","text":"https://secwatch.observer/filing/0001104659-22-115675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465922115675/0001104659-22-115675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465922115675/tm2229796d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:51:03.967161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1ebf239ea5400fd14cae8b71d899e08414e04d5","claim":"RHYTHM PHARMACEUTICALS, INC. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Rhythm Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465922115675/0001104659-22-115675-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}